ADIPOQ and metabolic dysfunction-associated steatotic liver disease: This was speculated to occur due to impaired hepatic and renal function, when NAFLD progresses to cirrhosis, but a dual effect of adiponectin cannot be excluded, i.e., adiponectin may shift from an advantageous to a disadvantageous contributor, when the disease progresses [67].